States' Case No Bellwether In Price-Fixing MDL, Teva Says

By Jeannie O'Sullivan · March 13, 2020, 4:54 PM EDT

Teva Pharmaceuticals and other generic-drug makers slammed a special master's recommendation that an antitrust suit by multiple states and territories be the bellwether in Pennsylvania-based multidistrict litigation, arguing it gives an...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Objection

Case Information

Case Title

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

August 05, 2016

Recent Articles By Jeannie

December 13, 2023
Pa. Justices Will Review Order Allowing Hospital Closure
April 13, 2022
Nursing Home Workers' Insurance Scam Claims Survive
April 06, 2022
Titan Of The Plaintiffs Bar: Joseph Saveri's Steven Williams
April 05, 2022
Valsartan MDL Judge OKs Out-Of-State Litigants, More Claims
March 31, 2022
Health Plans Squeezed By Opioid Drug Scheme, 3rd Circ. Told
March 16, 2022
Virus Whistleblower Suit Short On Specifics, NJ Officials Say
March 10, 2022
NJ Court Must Rethink Archer DQ In Dental Office Biz Dispute
March 04, 2022
Fact Disputes Keep Cardiac Hospital's ER Contract Row Alive
February 28, 2022
3rd Circ. Preview: March Roars With Ch. 11, Poaching Spats
February 22, 2022
Charities Ensnared In NJ Antitrust Suit Over Cancer Drugs